Candel Therapeutics, Inc. (CADL)

Market Cap	26.61M
Revenue (ttm)	n/a
Net Income (ttm)	-32.18M
Shares Out	28.92M
EPS (ttm)	-1.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,551
Open	0.930
Previous Close	0.920
Day's Range	0.920 - 0.950
52-Week Range	0.870 - 3.320
Beta	0.37
Analysts	Strong Buy
Price Target	7.00 (+660.87%)
Earnings Date	Nov 9, 2023

About CADL

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 27, 2021
• Employees: 76
• Stock Exchange: NASDAQ
• Ticker Symbol: CADL

Analyst Forecast

According to 3 analysts, the average rating for CADL stock is "Strong Buy." The 12-month stock price forecast is $7.0, which is an increase of 660.87% from the latest price.

Price Target

$7.0

(660.87% upside)

Analyst Consensus: Strong Buy